Aquavit Pharmaceuticals Forms Alliance Partnership with Accelrys
News Oct 14, 2012
Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and MAV-403 products. The partner agreement was signed on September 12, 2012. Under the terms of the partnership, Aquavit will utilize the scientifically aware Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine.
"It is an exciting opportunity for both companies. As a leading global provider of enterprise scientific informatics software, Accelrys is the ideal partner to accelerate achievement of Aquavit's vision. Having our products powered by the Accelrys Enterprise Platform will support our market leading science," said Sobin Chang, Aquavit's Chief Executive Officer.
"We are pleased to be partnering with Aquavit Pharmaceuticals to help accelerate the development of innovative personalized treatments," said Sanjay Gupta, Vice President of Corporate Development at Accelrys. "The Accelrys Enterprise Platform will advance these initiatives by providing unparalleled capabilities in managing end-to-end scientific workflows to achieve better outcomes."
This partnership will be led by Thomas S. Benjamin, Vice President of Technology at Aquavit Pharmaceuticals. Mr. Benjamin's award winning research has appeared in The New York Times and The Wall Street Journal. Mr. Benjamin said, "We aim to break new ground with the first-of-a-kind systems in our product lines. We are thrilled to be integrating the powerful Accelrys Enterprise Platform into the development of our next-generation medical technologies."
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE